Overview

* Pro-Dex ( PDEX ) fiscal Q1 revenue grows 24% yr/yr, beating analyst expectations

* Net income for fiscal Q1 more than doubles, aided by investment gains

* Gross margin declines due to higher costs, including tariffs

Outlook

* Company did not provide specific financial guidance in press release

Result Drivers

* NEXT-GEN HANDPIECE - Revenue increase driven by resumption of next-gen handpiece shipments to largest customer

* HIGHER COSTS - Gross margin decline attributed to higher costs, including tariffs, not fully passed to customers

* INCREASED EXPENSES - Operating expenses rose due to higher personnel costs in HR, IT, and facilities

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q1 Beat $18.53 $15.30

Revenue mln mln (1

Analyst)

Q1 EPS $1.40

Q1 Net $4.68

Income mln

Q1 Gross $5.36

Profit mln

Q1 $2.25

Operatin mln

g

Expenses

Analyst Coverage

* The one available analyst rating on the shares is "buy"

* The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

* Wall Street's median 12-month price target for Pro-Dex Inc ( PDEX ) is $56.00, about 45.2% above its October 29 closing price of $30.71

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)